-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
The Co-Founder of Kingworld Medicines Group Limited (HKG:1110), Li Sheng Zhao, Just Bought A Few More Shares
The Co-Founder of Kingworld Medicines Group Limited (HKG:1110), Li Sheng Zhao, Just Bought A Few More Shares
Even if it's not a huge purchase, we think it was good to see that Li Sheng Zhao, the Co-Founder of Kingworld Medicines Group Limited (HKG:1110) recently shelled out HK$280k to buy stock, at HK$0.52 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.
View our latest analysis for Kingworld Medicines Group
The Last 12 Months Of Insider Transactions At Kingworld Medicines Group
In fact, the recent purchase by Li Sheng Zhao was the biggest purchase of Kingworld Medicines Group shares made by an insider individual in the last twelve months, according to our records. Even though the purchase was made at a significantly lower price than the recent price (HK$0.58), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
SEHK:1110 Insider Trading Volume April 17th 2022There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Does Kingworld Medicines Group Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Kingworld Medicines Group insiders own about HK$238m worth of shares (which is 66% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Does This Data Suggest About Kingworld Medicines Group Insiders?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. When combined with notable insider ownership, these factors suggest Kingworld Medicines Group insiders are well aligned, and quite possibly think the share price is too low. That's what I like to see! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example, Kingworld Medicines Group has 4 warning signs (and 1 which shouldn't be ignored) we think you should know about.
Of course Kingworld Medicines Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Even if it's not a huge purchase, we think it was good to see that Li Sheng Zhao, the Co-Founder of Kingworld Medicines Group Limited (HKG:1110) recently shelled out HK$280k to buy stock, at HK$0.52 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.
即使这不是一笔巨大的收购,我们也认为很高兴看到百度的联合创始人李胜昭Kingworld医药集团有限公司(HKG:1110)最近斥资28万港元买入股票,每股0.52港元。尽管这笔购买规模不大,但无论从百分比还是绝对值来看,都可以被视为一个好兆头。
View our latest analysis for Kingworld Medicines Group
查看我们对Kingworld Medicines Group的最新分析
The Last 12 Months Of Insider Transactions At Kingworld Medicines Group
Kingworld Medicines Group最近12个月的内幕交易
In fact, the recent purchase by Li Sheng Zhao was the biggest purchase of Kingworld Medicines Group shares made by an insider individual in the last twelve months, according to our records. Even though the purchase was made at a significantly lower price than the recent price (HK$0.58), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
事实上,根据我们的记录,李胜照最近购买的是过去12个月内内部人士购买Kingworld Medicines Group股票的最大金额。尽管这笔收购的价格明显低于最近的价格(0.58港元),但我们仍然认为内幕收购是积极的。因为这些股票是以较低的价格购买的,所以这一次的买入并没有告诉我们多少内部人士对当前股价的看法。
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
你可以在下面看到过去12个月(由公司和个人)进行的内幕交易的直观描述。如果你点击图表,你可以看到所有的个人交易,包括股票价格、个人和日期!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
还有很多其他公司让内部人士买进股票。你很可能会这么做不想怀念这一切吗?免费内部人士正在收购的成长型公司名单。
Does Kingworld Medicines Group Boast High Insider Ownership?
Kingworld Medicines Group是否拥有高度的内部人持股?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Kingworld Medicines Group insiders own about HK$238m worth of shares (which is 66% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
看看一家公司的内部人持股总数,可以帮助你了解他们是否与普通股股东很好地结合在一起。我认为,如果内部人士持有该公司大量股份,这是一个好兆头。Kingworld Medicines Group内部人士持有价值约2.38亿港元的股票(占该公司66%的股份)。我喜欢看到这种程度的内部人持股,因为它增加了管理层考虑股东最佳利益的机会。
So What Does This Data Suggest About Kingworld Medicines Group Insiders?
那么,这些数据对Kingworld Medicines Group内部人士有何启示?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. When combined with notable insider ownership, these factors suggest Kingworld Medicines Group insiders are well aligned, and quite possibly think the share price is too low. That's what I like to see! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example, Kingworld Medicines Group has 4 warning signs (and 1 which shouldn't be ignored) we think you should know about.
最近的内部收购令人振奋。对过去一年交易的分析也给了我们信心。再加上值得注意的内部人持股,这些因素表明Kingworld Medicines Group的内部人很好地结盟,很可能认为股价太低了。这就是我想看到的!因此,这些内幕交易可以帮助我们建立一个关于股票的论文,但了解这家公司面临的风险也是值得的。例如,Kingworld Medicines Group有4个警告信号(其中1个不应被忽视),我们认为您应该知道。
Of course Kingworld Medicines Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然了Kingworld Medicines Group可能不是最值得买入的股票。所以你可能想看看这个免费汇集了高质量的公司。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
这篇由《华尔街日报》撰写的文章本质上是笼统的。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。简单地说,华尔街在提到的任何股票中都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧